Trump On Right-to-Try: Gottlieb's 'Heading It Up'?
Executive Summary
Curious comment by president could place US FDA Commissioner in tough spot balancing his boss' priorities with his and staff's concerns about pending right-to-try legislation.
You may also be interested in...
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.
US FDA Right To Try Policy: For Now, Defer Questions To Sponsors, Bill Text
Agency tells staff that it should refer patient questions about the law to the drug sponsor, while sponsors should be told to read the statute if they inquire about it.